U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06923397) titled 'Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial' on April 04.
Brief Summary: This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Lymphoma, Hodgkin
Lymphoma, Non-Hodgkin
Sedentary Behavior
Intervention:
BEHAVIORAL: Interrupte...